MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
P/B ratio for MyMD Pharmaceuticals, Inc. (MYMD)
P/B ratio as of 2023: 0.94
According to MyMD Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.94. At the end of 2022 the company had a P/B ratio of 3.04.
P/B ratio history for MyMD Pharmaceuticals, Inc. from 2005 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.94 |
| 2022 | 3.04 |
| 2021 | 8.97 |
| 2020 | -2.67 |
| 2019 | 0.21 |
| 2018 | 127.54 |
| 2017 | 8.38 |
| 2016 | 182.73 |
| 2015 | 56.52 |
| 2014 | 76.73 |
| 2013 | 128.05 |
| 2012 | 87.80 |
| 2011 | 56.07 |
| 2010 | 37.60 |
| 2009 | 33.50 |
| 2008 | 12.83 |
| 2007 | -297.28 |
| 2006 | -45.08 |
| 2005 | 33.97 |